Chondroprotective functions of neutrophil-derived extracellular vesicles by promoting the production of secreted frizzled-related protein 5 in cartilage Authors: Keita Kitahara, Taku Ebata, Chen Liyile, Yoshio Nishida, Yuki Ogawa, Taiki Tokuhiro, Junki Shiota, Tatsuya Nagano, Taichi E. Takasuka, Tsutomu Endo, Tomohiro Shimizu, Hend Alhasan, Tsuyoshi Asano, Daisuke Takahashi, Kentaro Homan, Tomohiro Onodera, Ken Kadoya, M. Alaa Terkawi, Norimasa Iwasaki Published: 2024 ABSTRACT BackgroundOsteoarthritis (OA) is the most common degenerative joint disease characterized by cartilage degradation and various degrees of inflammation in the synovium. Growing evidence highlights that neutrophil extracellular vesicles (EVs) play a protective role in arthritic joints by promoting the resolution of inflammation and the synthesis of proteoglycans in cartilage. However, this homeostatic function is dependent on the activation state of neutrophils and the surrounding environment/tissues. Hence, we explored the chondroprotective functions of neutrophil-derived EVs under different stimulation conditions and the underlying molecular mechanism.MethodsHuman blood-derived neutrophils, murine bone marrow-derived neutrophils, C-28I2 cells and primary chondrocytes were used. Neutrophils were stimulated with different cytokines, and their EVs were isolated for chondrocyte stimulation and further subjected to RNA-sequencing analysis. Two experimental murine OA models were used, and the treatment was performed by intraarticular injections.ResultsConditioned medium from neutrophils stimulated with TGF-β (N-β) had the greatest inhibitory effect on the expression of catabolic factors in stimulated chondrocytes. These protective effects were not impaired when conditioned medium of N-β from AnxA1-deficient mice was used. Consistent with these results, EVs isolated from N-β significantly reduced the expression of catabolic factors in stimulated chondrocytes. Bulk RNA-seq analysis revealed that secreted frizzled-related protein 5 (SFRP5) is upregulated in N-β-EV-stimulated chondrocytes. Furthermore, recombinant SFRP5 treatment significantly reduced the expression of catabolic factors in vitro and catabolic process in experimental murine OA models.ConclusionsThe current study emphasizes the potential therapeutic application of neutrophils in OA and provides new knowledge on the molecular mechanisms underlying their function.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12964-024-01953-8. Introduction Osteoarthritis (OA) is the most prevalent degenerative joint disease that causes disability in the majority of elderly people, especially those older than 55 years. The prevalence of this disease is expected to increase due to the dramatic growth of the elderly population worldwide and the lack of specific and preventive therapeutics. The major pathological features of OA include progressive cartilage degradation and the development of low-grade inflammation (LGI) in the synovium [1–3]. Current approaches for managing this disease include nonpharmacological, pharmacological, and surgical interventions. While nonpharmacological approaches such as body weight loss and exercise are prescribed at the early stage of OA to reduce stress on cartilage, pharmacological approaches include the use of therapeutic agents for reducing pain and improving functionality and quality of daily life. Surgical intervention for total joint arthroplasty is the only option for restoring the function of the joint at the end-stage of the disease. Therefore, there is a need for the development of preservative and specific treatments for OA, and this requires a better understanding of the cellular and molecular mechanisms by which the body restores the homeostatic state of affected tissues [3]. The OA process is initiated when articular cartilage wear and matrix extracellular proteins are released in the joint space and activate immune cells by signaling damage-associated molecular patterns (DAMPs), resulting in the development of LGI in the synovium. The persistence of the LGI promotes chondrocyte hypertrophy, which cannot maintain equilibrium between the breakdown and synthesis of the matrix, leading to excessive cartilage loss [3, 4]. The immune cells involved in the pathological process of OA include macrophages and lymphocytes, which are the most abundant populations, and neutrophils, which are the least abundant cell type in synovial tissue and fluids. Neutrophils are the first immune cells to enter the synovium after joint injury and seem to play fundamental roles in both pathogenic and homeostatic processes in arthritic joints [5–7]. Their homeostatic functions, including orchestrating the resolution of inflammation, the recruitment of immune cells and the synthesis of glycosaminoglycans (GAGs) in cartilage, are most likely dependent on their activation state and the content of their secretomes [5, 8, 9]. Recent findings have demonstrated that extracellular vesicles (EVs) of neutrophils enter cartilage and protect joints in inflammatory arthritis by promoting TGF-β production and matrix deposition and restoring chondrocyte homeostasis in a mechanism dependent on Annexin 1 A (AnxA1) [10]. These findings support the protective function of neutrophils in cartilage and shed light on new strategies for developing innovative therapeutics for treating cartilage damage in arthritic joints. EVs are the major cellular secretomes that mediate intercellular communication and are known to play a key role in restoring homeostasis in tissues. They are membrane-derived vesicles that are 40 to 1,000 nm in size and contain numerous types of bioactive molecules, including metabolites, proteins, lipids, messenger RNAs, microRNAs, and DNA. However, the physiological and homeostatic functions of EVs are dependent on their contents, which largely rely on the activation and characteristics of the secreted cells. For instance, EVs can propagate pathogenic proteins or genetic contents that perpetuate neuroinflammation and neurodegeneration, resulting in significant brain dysfunction in Alzheimer’s disease (AD) and Parkinson’s disease (PD) [11, 12]. Likewise, EVs secreted by the tumor environment can prime metastasis and promote a procoagulant state in patients. EVs from inflammatory macrophages seem to promote plaque formation in atherosclerosis, tissue fibrosis in idiopathic pulmonary fibrosis and a severe proinflammatory state in arthritis [13–16]. On the other hand, the immunomodulatory properties and therapeutic effects of EVs have been documented in various experimental and clinical studies of different diseases. In fact, EVs from MSCs and neutrophils exert protective effects on cartilage by inhibiting the expression of catabolic factors and related signaling pathways in chondrocytes [17–19]. Despite the promising therapeutic action of EVs, many issues regarding reproducibility, cell sources and activation state remain obstacles to establishing this approach for standard treatment. Thus, in the current study, we investigated the functional characteristics of EVs derived from stimulated neutrophils and their protective effects on cartilage in vitro and in vivo. Our results provide additional insight into the potential therapeutic application of neutrophil-derived EVs and their molecular mechanisms in OA. Methods Study approval The use of human samples was approved by the Hokkaido University Institutional Review Board, and informed consent was obtained from the patients (Approval IDs. 018–0215 & 014–0144). Samples were obtained from knee OA-diagnosed patient (left knee OA male 84-year old) at Hokkaido University Hospital. Procedures for animal experiments were performed based on ethical guidelines approved by the Institute of Animal Care and Use Committee of the Hokkaido University Graduate School of Medicine (approval ID:18–0171) [16]. All animals were specific pathogen-free and purchased from Clea (Tokyo, Japan) and were kept in a specific-pathogen-free (SPF) facility during the experiments. Neutrophil isolation and stimulation Blood was collected from healthy donors using BD Vacutainer tubes containing ACD (Becton, Dickinson and Company, NJ, USA). Human neutrophils were isolated using Ficoll-Paque™ PLUS (GE Healthcare) [20]. The cells were cultured in MEM (Sigma) and then stimulated with either TNF-α (BioLegend, San Diego, CA, US) or TGF-β (Accession # P01137; BioLegend) for 30 min at a concentration of 50 ng/ml (DMEM low glucose; Sigma). One additional group of cells was stimulated with 50 ng/ml TGF-β plus 100 µM rosiglitazone (AdiopGen, San Diego, CA, USA) for 30 min. After 3 washes with phosphate-buffered saline (PBS; NACALAI TESQUE, Kyoto, Japan), the cells were placed in transwell inserts (Falcon cell culture inserts, BD, Franklin Lakes, NJ, USA) for further coculture with C-28I2 (Merck, Darmstadt, Germany). C-28I2 (5 × 105) chondrocytes were seeded on 24-well plates with micromass, cultured in high glucose DMEM (Sigma‒Aldrich) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma‒Aldrich) and penicillin/streptomycin (Wako) overnight, and then stimulated with DMEM + F12 + 1% ITS (Sigma) for 24 h. Next, the chondrocytes were stimulated with 30 ng/ml IL-1β (BioLegend) for 1 h, washed 3 times with PBS (Nacalai Tesque), and cocultured with freshly isolated neutrophils. The transwell inserts containing neutrophils were removed after 4 h, and C-28I2 chondrocytes were cultured alone for 20 h. Primary human chondrocytes were isolated from cartilage that was obtained from OA patients who undergoing total knee arthroplasty. The cartilage samples were minced into 1-mm3 pieces and digested with a 0.15% collagenase II solution (Gibco) in DMEM/F12 medium overnight at 37 ℃-shaking water-bath. The isolated chondrocytes were suspended in DMEM-F12 supplemented with 10% heat-inactivated FBS (Sigma-Aldrich), 2mM L-Glutamine, 25 mg/L penicillin/streptomycin. Cells were used for stimulation experiments after 1 passage. In a separate experiment, bone marrow-derived neutrophils from C57BL/6J or AnxA1-deficient mice were isolated using the Neutrophil Isolation Kit (Miltenyi Biotecs, CA, US) and stimulated for 30 min. AnxA1-deficient mice were generated using CRISPR/Cas9 technique as earlier described [20]. The cells were subsequently washed with PBS (Nacalai Tesque) and cultured in DMEM-Low glucose (Sigma‒Aldrich) supplemented with 10% FBS and penicillin/streptomycin for 4 h. Cells were stimulated with a same manner as used in human cells for preparing of conditioned medium and isolation of EVs. The conditioned media were harvested for further use to culture chondrocytes. Primary articular chondrocytes were isolated from the knee cartilage of 5–6-day-old C57BL/6J mice after treatment with collagenase D (Sigma–Aldrich) in DMEM for enzymatic digestion at 37 °C overnight [16]. The isolated cells were suspended in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma‒Aldrich), 2 mM L-glutamine, and 25 mg/L penicillin/streptomycin and seeded onto 24-well plates at a ratio of 2 × 105 for stimulation with 10 ng/ml IL-1β (BioLegend). The conditioned media of neutrophils were used to cultivate primary chondrocytes for 24 h. All in vitro experiments were performed in triplicate, and all experiments were repeated at least two times. Isolation and characterization of extracellular vesicles The freshly isolated neutrophils were treated with 50 ng/ml TGF-β (BioLegend) plus 100 µM rosiglitazone (KOM) for 3 h in MEM supplemented with 10% exosome-depleted, heat-inactivated FBS (System Biosciences, Palo Alto, CA), 1 mM L-glutamine, and 25 mg/L penicillin/streptomycin. The culture medium was then collected and centrifuged at 400 × g for 5 min at 4 ℃ to remove cells and at 2000 × g for 10 min to remove dead cells. Then, the culture medium was filtered through a 1.2 μm filter unit (Sartorius Minisart® syringe filter, Sartorius, Goettingen, Germany) to eliminate cell debris. The medium was ultraccentrifuged at 100000 × g for 70 min at 4 ℃ (L-80XP, Beckman Coulter, California, USA), washed once with 50 ml of PBS (Nacalai Tesque) and centrifuged again under the same conditions to isolate the EVs. The isolated EVs were suspended in 100 µl of ice-cold PBS (Nacalai Tesque) and stored at -80 ℃ until use. EVs were obtained using a MagCapture™ Exosome Isolation Kit PS Ver2. (Wako, Japan) according to the manufacturer’s instructions. The isolated EVs were lysed by ultrasonication (UD-100. An ultrasonic disruptor (TOMY SEIKO Co., Ltd., Japan) was used to determine the protein concentration via a BCA protein assay (Thermo Fisher Scientific, Tokyo, Japan). The samples were kept at -80 °C for Western blotting and proteomic analyses. For further characterization of the isolated EVs, particle size distribution analysis was performed using ELSZneo (Otsuka Electoronics, Osaka, Japan), and morphological examination was performed by transmission electron microscopy. Stimulation of human C-28I2 cell line and murine primary chondrocytes C-28I2 (Merck) chondrocytes (5 × 105) were seeded on 24-well plates and differentiated in medium DMEM + F12 + 1% ITS (Sigma) for 24 h. Cells were next stimulated with 20 ng/ml IL-1β (BioLegend) in presence or absence of 5µg/ml EVs for 24 h. On the other hand, freshly isolated chondrocytes from knee cartilage of mice were seeded onto 24-well plates at a ratio of 2 × 105, incubated for 24 h at 37 °C, and then stimulated with 10 ng/ml IL-1β in the presence or absence of 5µg/ml EVs or 100 ng/ml SFRP5 (R&D Systems) for 24 h. Afterwards, the chondrocytes were harvested for analysis of gene and protein expression. Western blotting Neutrophil-derived EVs and chondrocytes were lysed in RIPA lysis buffer (ATTO Corporation, Tokyo, Japan), and the lysate samples were subjected to standard SDS‒PAGE and Western blot analysis (ATTO) procedures. For each experiment set, equalized protein concentration was used for loading in SDS-PAGE. The target proteins were detected with the specific antibodies listed in Supplementary Table S1. The blots were washed and incubated with the corresponding secondary HRP-conjugated antibodies (CST, MA, USA) for 1 h. After the blots were washed, solutions from the EZ WestLumi Plus Kit (ATTO) were applied, the bands were visualized using an iBright 1500 Imaging System (Thermo Fisher Scientific, Inc., USA), and the bands were quantified for relative intensity based on the density of each target relative to the band density of β-actin or GAPDH (ImageJ, NIH). Protein sample preparation and proteomic analysis A total of 5 µg of protein samples from EVs in the N0 and N2 groups were subjected to TCA precipitation, followed by 2 washes with ice-cold acetone (Wako). Proteins were suspended in 10 µL of 8 M urea, and 70 µL of 50 mM ammonium bicarbonate buffer was added to each sample. The samples were treated with 50 mM dithiothreitol for 30 min at 50 °C and 500 mM iodoacetamide for 30 min in the dark for the alkylation reaction. Protease digestion was performed using a 1:112.5 trypsin/protein ratio (proteomic grade; Roche, Mannheim, Germany) for 15 h at 37 °C. Tryptic peptides were purified by a C18 ZipTip pipette tip (Merck Millipore, Burlington, MA) and eluted in 0.1% formic acid in Milli-Q water. Mass spectra were obtained by an Easy nLC1000 liquid chromatography system with a Q Exactive plus Orbitrap mass spectrometer (Thermo Fisher Scientific, Illinois, USA) and Xcalibur software v. 3.1 (Thermo Fisher Scientific). The tryptic peptides were separated on a C18 capillary tip column (NTCC-360/75-3-125; Nikkyo Techno, Japan) by a linear gradient from 5 to 30% with two solutions, 0.1% formic acid in water (solution A) and 0.1% formic acid in acetonitrile (solution B), for 120 min at a flow rate of 300 nL/min. Fullscan mass spectra were obtained with an Orbitrap mass spectrometer with a scan range of 300.0 to 2,000.0 m/z. The full-scan automatic gain control (AGC) was 1e6 at 70,000 resolution, and the full-scan maximum injection time was 200 ms. The MS2 scan AGC target was 1e5 at 17,500 resolution, and the MS2 scan maximum injection time was 60 ms. The dynamic exclusion time was 10 s, and the isolation window was 2.0 m/z. The peptide charge was set at + 2, +3, and + 4. For data processing, the raw MS files were analyzed by Proteome Discoverer v. 2.1 (Thermo Fisher Scientific) with all coding sequences of Homo sapiens (https://www.uniprot.org/proteomes/UP000005640). Proteins were identified from the acquired MS/MS spectra. The maximum missed cleavage, carbamidomethylation on cysteine as a static modification, and dynamic oxidation on methionine were used. The precursor mass tolerance was set at 10 ppm, and the fragment mass tolerance was set at 0.02 Dalton. The strict target false discovery rate (FDR) for highly confident peptide hits was set to 1%. Gene expression analysis by quantitative real-time reverse transcription polymerase chain reaction (qRT‒PCR) Chondrocyte RNA was purified using TRIzol Reagent (Invitrogen Carlsbad, CA, USA) and an RNA extraction kit (NucleoSpin® RNA, TAKARA, Tokyo, Japan) and then subjected to GoScriptTM reverse transcriptase for cDNA synthesis (Promega, Madison, USA). SYBR Premix Ex TaqTM II (Takara, Shiga, Japan) was used to perform qRT‒PCR using a Thermal Cycler Dice System 2 (Takara). The sequences of primers used for each target are listed in Supplementary Table S2 [16]. Gene expression was calculated using the 2−ΔΔCt method with normalization to the baseline housekeeping gene expression. Ex vivo femoral head cartilage explant culture Femoral head cartilage isolated from 6-week-old C57BL/6 mice (SPF, Clea) was washed twice with ice-cold PBS (Nacalai Tesque), placed in 96-well plates (1 in each well) and then cultured in low-glucose DMEM supplemented with 10% FBS and 25 mg/L penicillin/streptomycin for 48 h [16]. Cartilage samples were stimulated with 10 ng/ml recombinant IL-1β (Biolegend) in the presence or absence of 10 µg/ml EVs or 100 ng/ml recombinant SFRP5 (R&D, Minneapolis, MN, US) for 72 h. For histologic assessment, cartilage samples were fixed in 4% PFA (Wako, Japan) for 48 h at 4 ℃, decalcified with EDTA solution (Wako) for 2 weeks and then embedded in paraffin. Section (5 μm thick) were prepared and stained with hematoxylin, eosin and Safranin O/Fast Green (Wako). The microscopy images were subjected to ImageJ (National Institutes of Health; NIH, USA) for assessment of pathological changes in the cartilage. Qualifications were carried out based on Safranin O/Fast green staining of the superficial area of the articular cartilage, which was subtracted from the total area [16]. In vivo OA models Collagenase-induced OA (CIOA) was induced by two intra-articular injections of 0.25 unit/µl type VII collagenase solution (Sigma) on days 0 and 2 (6 µl) in the left knee joint of 8-week-old male C57BL/6 mice (Clea). An unstable OA model was surgically induced by transection of the anterior cruciate ligament (ACLT) [16]. Recombinant SFRP5 (R&D) was intra-articularly administered twice a week for 4 weeks at a concentration of 0.1 mg/kg. The control mice received 10 µl of PBS (Nacalai Tesque) as a vehicle. The left knee joints were harvested after 6 weeks for histological assessments. Knees were fixed with 10% formalin for 24 h, decalcified by treatment with EDTA for 1 week, and then embedded in paraffin. Section (5 µM thick) were cut and stained with hematoxylin and eosin (H&E) and Safranin O–fast green (Wako). Cartilage lesions were evaluated based on the semiquantitative scoring model of the Osteoarthritis Research Society International (OARSI) cartilage for OA histopathology (score range 0–24). Synovitis and osteophyte formation scores were evaluated in stained Sect. [16]. The histological scores were determined blindly by two different people. RNA sequencing and bioinformatics Libraries were generated from 1 µg of high-quality RNA (NEB Next Ultra II Directional RNA Library Prep Kit (MA, USA)) and sequenced using an Illumina NovaSeq 6000 (Illumina). Data of 150 bp× 2 paired-ends of 4-6G bases per sample (3 samples for each condition) were trimmed by fastp and mapped by alignment to the mouse mm10 reference genome using STAR. The reads were quantified using RSEM, and the raw count data were subjected to Subio Platorm Plug-ins software (Tokyo, Japan) to determine the differentially expressed genes (DEGs) and fold changes. The level of significance was set up based on the false discovery rate (FDR) to be FDR < 0.05. Gene Ontology (GO) and pathway enrichment analyses were performed using a public database for A Gene Annotation & Analysis Resource Metascape (https://metascape.org/gp/index.html#/main/step1). Data visualization and graphing were performed using SRplot tools (http://www.bioinformatics.com.cn/srplot) [21]. Statistical analysis No statistical methods were used to determine the sample size, but all experiments were performed with a sufficient sample size for statistical analysis. Statistical analysis of the data was performed using Prism (GraphPad Software Inc., USA). One-way analysis of variance (ANOVA) followed by Tukey’s multiple-comparison procedure was used to compare the differences among groups, and Student’s test was used to compare the differences between two independent groups. The results were considered statistically significant when p < 0.05. Results Secretomes of TGF-β-stimulated neutrophils suppress chondrocyte catabolic factors induced by IL-1β stimulation To first optimize the stimulation conditions of neutrophils associated with chondroprotective effects, human neutrophils were stimulated with either TNF-α (N-α) or TGF-β (N-β) and then co-cultured with IL-1β-stimulated human chondrocyte cell line C-28I2 using tarnswell inserts. Cocultured chondrocytes with nonstimulated (N-non) and stimulated neutrophils exhibited various degrees of inhibition of the expression of catabolic factors, including MMP3, MMP13 and IL-6 (Fig. 1A). Notably, among these stimulated neutrophils, N-β exhibited the greatest inhibitory effects on the expression of catabolic factors induced by IL-1β stimulation in chondrocytes. To confirm these findings, conditioned medium harvested from nonstimulated and stimulated murine bone marrow-derived neutrophils was used to culture primary IL-1β-stimulated chondrocytes. Consistent with observations in human cells, N-β-conditioned medium had the greatest inhibitory effect on the expression of catabolic factors in primary murine chondrocytes (Fig. 1B-D & Supplementary Fig. S1A). Moreover, this treatment slightly improved the expression of anabolic factors, including COL2 in chondrocytes (Supplementary Fig. S1B). To further support our findings, we added rosiglitazone, a PPAR-γ agonist that inhibits neutrophil death, resulting in reduced cell debris in the conditioned medium, to TGF-β-stimulated neutrophils. Murine neutrophils stimulated with TGF-β + rosiglitazone (N-β + R) exhibited inhibitory effects comparable to those of neutrophils stimulated with TGF-β alone (Supplementary Fig. S1C), suggesting that TGF-β stimulation promoted the anticatabolic function of neutrophils in cartilage by suppressing the expression of catabolic factors in chondrocytes. Given earlier findings showing that the anticatabolic function of neutrophils in cartilage is dependent on AnxA1 [10], we examined the anticatabolic function of N-β-conditioned medium from AnxA1-deficient mice. Importantly, conditioned medium from the N-β of AnxA1-deficient mice inhibited the expression of catabolic factors in murine chondrocytes (Fig. 1E). Our collective findings revealed that N-β secretomes exhibited chondroprotective effects by reducing the production of catabolic factors induced by IL-1β stimulation via a mechanism that appears to be independent of AnxA1. Fig. 1Chondroprotective functions of TGF-β-stimulated neutrophils in vitro. A) Effect of coculturing chondrocytes with nonstimulated (N-non) and TNF-α (N-α)- or TGF-β (N-β)-stimulated neutrophils on the expression of catabolic factors induced by IL-1β stimulation using a Transwell insert system. B-D) Effect of conditioned medium from nonstimulated (N-non) and TNF-α (N-α)- or TGF-β (N-β)-stimulated neutrophils on the expression of catabolic factors. Human neutrophils were stimulated with either TNF-α (N-α) or TGF-β (N-β) and then co-cultured with IL-1β-stimulated human chondrocyte cell line C-28I2 using tarnswell inserts. B) Gene expression as determined by qRT‒PCR. C) Protein expression as determined by Western blot analysis. D) Quantification of the relative densities of the detected bands. E) Effect of conditioned medium from nonstimulated (N-non) and TNF-α (N-α)- or TGF-β (N-β)-stimulated neutrophils from AnxA1-deficient mice on the expression of catabolic factors. The results are presented as the means ± SEMs of relative gene expression or band densities. In the bar charts, the symbols represent individual samples. Significance was determined using one-way analysis of variance. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. ns = not significant Chondroprotective functions of TGF-β-stimulated neutrophils in vitro. A) Effect of coculturing chondrocytes with nonstimulated (N-non) and TNF-α (N-α)- or TGF-β (N-β)-stimulated neutrophils on the expression of catabolic factors induced by IL-1β stimulation using a Transwell insert system. B-D) Effect of conditioned medium from nonstimulated (N-non) and TNF-α (N-α)- or TGF-β (N-β)-stimulated neutrophils on the expression of catabolic factors. Human neutrophils were stimulated with either TNF-α (N-α) or TGF-β (N-β) and then co-cultured with IL-1β-stimulated human chondrocyte cell line C-28I2 using tarnswell inserts. B) Gene expression as determined by qRT‒PCR. C) Protein expression as determined by Western blot analysis. D) Quantification of the relative densities of the detected bands. E) Effect of conditioned medium from nonstimulated (N-non) and TNF-α (N-α)- or TGF-β (N-β)-stimulated neutrophils from AnxA1-deficient mice on the expression of catabolic factors. The results are presented as the means ± SEMs of relative gene expression or band densities. In the bar charts, the symbols represent individual samples. Significance was determined using one-way analysis of variance. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. ns = not significant EVs from TGF-β-stimulated neutrophils exert chondroprotective effects against IL-1β stimulation in cartilage Given that EVs are the most powerful components of neutrophil secretomes, EVs were isolated from N-β, and their anabolic functions were examined in vitro and ex vivo. EVs isolated from N-β via ultracentrifugation demonstrated the typical morphologies of EVs, with an average size of 147.7 nM, and contained cytosolic and transmembrane markers such as TSG101, CD9 and AnxA1 (Fig. 2A, B). Proteomic analysis of EVs revealed that N-non-EVs contained 530 proteins, and 249 proteins were found in N-β-EVs. These proteins encode membrane, cytosolic and transcription factors that are frequently found in EVs from other cells (Supplementary Tables S3 & S4). Importantly, EVs from N-β were able to significantly reduce the expression of MMP3 and MMP13 in both human and primary mouse IL-1β-stimulated chondrocytes (Fig. 2C). Treatment with N-β EVs elevated the expression of Col2 and Acan was in IL-1β-stimulated murine chondrocytes (Supplementary Fig. S2A, B). The anabolic functions of N-β-EVs were also evident in IL-1β-stimulated primary chondrocytes that were isolated from OA cartilage (Supplementary Fig. S2C-D). Similarly, EVs from human N-β isolated using a commercial kit exhibited a comparable inhibitory effect on the expression of MMP13 in IL-1β-stimulated C-28I2 chondrocytes (Fig. 2D). The uptake of EVs from N-β by human chondrocytes was observed after 3 h of incubation (Fig. 2E). In line with these results, EVs from murine N-β attenuated the catabolic process induced by IL-1β in cartilage by increasing safranin O staining in the superficial zone of femoral head cartilage (Fig. 2F, G). Taken together, these findings revealed that EVs from N-β have the typical morphological and molecular features of EVs and exert anti-catabolic effects in cartilage to be the most potent for therapeutic application. Fig. 2Characterizations of EVs from TGF-β-stimulated neutrophils and their effects in vitro and ex vivo. A) Characterization of EVs from TGF-β-stimulated neutrophils isolated by ultracentrifugation, showing the size distribution analysis (left) and representative transmission electron microscopy images of EVs (upper right). B) Detection of EV markers by Western blot analysis. C, D) Effect of EVs from TGF-β-stimulated neutrophils on the expression of catabolic factors in human chondrocyte cell line C-28I2 and primary mouse chondrocytes. Western blot analyses were subsequently performed. D) Gene expression of MMP13 in chondrocytes stimulated with EVs. In the left panel, EVs were isolated via ultracentrifugation, and in the right panel, EVs were isolated from neutrophils using a commercial kit. The results represent the mean ± SEM of the relative gene expression. E) In vitro cellular uptake of EVs by primary murine chondrocytes. Membranes of EVs were first labeled with red fluorescent protein (RFP) and then added to primary chondrocyte cultures for 3 h. Arrows indicate the uptake of EVs by chondrocytes. F, G) Ex vivo stimulation of mouse cartilage by EVs from TGF-β-stimulated neutrophils. F) Representative images of Safranin O staining of sectioned femoral head cartilage after stimulation. Scale bars = 50 μm. G) Quantification of Safranin O staining in the superficial zone of sectioned cartilage. In the bar charts, the symbols represent individual samples. Significance was determined using one-way analysis of variance. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. ns = not significant Characterizations of EVs from TGF-β-stimulated neutrophils and their effects in vitro and ex vivo. A) Characterization of EVs from TGF-β-stimulated neutrophils isolated by ultracentrifugation, showing the size distribution analysis (left) and representative transmission electron microscopy images of EVs (upper right). B) Detection of EV markers by Western blot analysis. C, D) Effect of EVs from TGF-β-stimulated neutrophils on the expression of catabolic factors in human chondrocyte cell line C-28I2 and primary mouse chondrocytes. Western blot analyses were subsequently performed. D) Gene expression of MMP13 in chondrocytes stimulated with EVs. In the left panel, EVs were isolated via ultracentrifugation, and in the right panel, EVs were isolated from neutrophils using a commercial kit. The results represent the mean ± SEM of the relative gene expression. E) In vitro cellular uptake of EVs by primary murine chondrocytes. Membranes of EVs were first labeled with red fluorescent protein (RFP) and then added to primary chondrocyte cultures for 3 h. Arrows indicate the uptake of EVs by chondrocytes. F, G) Ex vivo stimulation of mouse cartilage by EVs from TGF-β-stimulated neutrophils. F) Representative images of Safranin O staining of sectioned femoral head cartilage after stimulation. Scale bars = 50 μm. G) Quantification of Safranin O staining in the superficial zone of sectioned cartilage. In the bar charts, the symbols represent individual samples. Significance was determined using one-way analysis of variance. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. ns = not significant Treatment with N-β EVs increases the expression of SFRP5 and exerts chondroprotective effects To further explore the mechanism by which N-β EVs suppress the production of catabolic factors, the gene expression of stimulated C-28I2 chondrocytes was analyzed by bulk RNA-seq. Stimulation of chondrocytes with IL-1β resulted in significant upregulation (FDR > 0.05, FC > 1) of 168 genes, 282 genes in the presence of EVs-N-none and 161 genes in the presence of EVs-N-β (Supplementary Table S5). Venn diagram analysis revealed that 168 genes upregulated in chondrocytes stimulated with IL-1β, 101 genes upregulated in chondrocytes stimulated with IL-1β + EVs-N-none and 92 genes upregulated in chondrocytes stimulated with IL-1β + N-β (Fig. 3A). On the other hand, 168 genes were upregulated in chondrocytes stimulated with IL-1β + EVs-N-none, and 56 genes were upregulated in chondrocytes stimulated with IL-1β + N-β (Fig. 3A). KEGG pathway enrichment analysis revealed that the differentially upregulated genes in IL-1β-stimulated chondrocytes were most significantly enriched in the IL-17 signaling, TNF signaling, cytokine‒cytokine receptor interaction, and NOD-like receptor signaling pathways (Fig. 3B). GO analysis for biological process and molecular function demonstrated that these upregulated genes are involved in cell activation and cytokine and chemokine activities (Fig. 3C & Supplementary Fig. S3). Notably, the expression of genes enriched in these terms was dramatically reduced in chondrocytes treated with EVs-N-β (Fig. 3D). In addition, the 56 genes that were specifically upregulated in chondrocytes stimulated with IL-1β + N-β were enriched in metabolic pathway terms (p = 0.0322; which included AKR1B1, AMY2B, ST8SIA5, PDE6A, ST6GAL2, PLA2G4C, GDA, CKM, CKMT1A, and DBH) (Fig. 3E), which may reflect the anticatabolic function of N-β EVs. Among the genes that were significantly upregulated in N-β EV-treated chondrocytes, SFRP5 has been selected as molecular candidate involved in the anti-inflammatory responses. Furthermore, increased expression of SFRP5 was evident in C-28I2 chondrocytes and murine primary chondrocytes after treatment with N-β EVs (Fig. 3F, G). SFRP5 was detected in the synovial fluid and cartilage tissue of the knee of patients with OA (Fig. 3H, I). In addition, SFRP5-stained cells appeared in different regions of normal murine cartilage and the numbers of positive cells were significantly decreased in experimental murine knee OA as compared to sham knee (Fig. 3J, K). Fig. 3Gene profile of C-28I2 chondrocytes stimulated with IL-1β and neutrophil-derived EVs. A) Venn diagram analysis for the numbers of genes significantly upregulated in cells stimulated with IL-1β (blue), IL-1β + EVs-N-non (yellow), and IL-1β + EVs-N-β (green) in comparison to mock cells and in cells stimulated with IL-1β + EVs-N-β (red) in comparison to those stimulated with IL-1β + EVs-N-non (n = 3 for each condition). B, C) Gene enrichment analysis for pathways and biological process terms of differentially upregulated genes in chondrocytes stimulated with IL-1β. D) Heatmap of genes involved in the inflammatory response and catabolic process in cartilage in stimulated chondrocytes. E) Heatmap of genes involved in metabolic processes in stimulated chondrocytes. F) Expression of SFRP5 in C-28I2 chondrocytes stimulated with EVs. The results represent the mean ± SEM of the relative gene expression (n = 9), and the significance was determined using one-way analysis of variance. G) Expression of SFRP5 in primary chondrocytes stimulated with EVs, as analyzed by Western blot analysis. H) Detection of SFRP5 in the synovial fluid of 2 OA patient samples. I) Detection of SFRP5 in OA cartilage tissues by immunohistochemical staining. J) Detection of SFRP5 in normal murine femoral head cartilage. K) Detection of SFRP5 in experimental ACL-OA knee. Scale bars = 100 μm. The right panel represents the quantification of SFRP-5 positive cells in the knee cartilage. In the bar charts, the symbols represent individual samples. Significance was determined using two-tailed Student’s t test Gene profile of C-28I2 chondrocytes stimulated with IL-1β and neutrophil-derived EVs. A) Venn diagram analysis for the numbers of genes significantly upregulated in cells stimulated with IL-1β (blue), IL-1β + EVs-N-non (yellow), and IL-1β + EVs-N-β (green) in comparison to mock cells and in cells stimulated with IL-1β + EVs-N-β (red) in comparison to those stimulated with IL-1β + EVs-N-non (n = 3 for each condition). B, C) Gene enrichment analysis for pathways and biological process terms of differentially upregulated genes in chondrocytes stimulated with IL-1β. D) Heatmap of genes involved in the inflammatory response and catabolic process in cartilage in stimulated chondrocytes. E) Heatmap of genes involved in metabolic processes in stimulated chondrocytes. F) Expression of SFRP5 in C-28I2 chondrocytes stimulated with EVs. The results represent the mean ± SEM of the relative gene expression (n = 9), and the significance was determined using one-way analysis of variance. G) Expression of SFRP5 in primary chondrocytes stimulated with EVs, as analyzed by Western blot analysis. H) Detection of SFRP5 in the synovial fluid of 2 OA patient samples. I) Detection of SFRP5 in OA cartilage tissues by immunohistochemical staining. J) Detection of SFRP5 in normal murine femoral head cartilage. K) Detection of SFRP5 in experimental ACL-OA knee. Scale bars = 100 μm. The right panel represents the quantification of SFRP-5 positive cells in the knee cartilage. In the bar charts, the symbols represent individual samples. Significance was determined using two-tailed Student’s t test To further elucidate the role of SFRP5 in cartilage catabolism, primary murine chondrocytes were stimulated with IL-1β in the presence or absence of SFRP5, and the expression of catabolic factors was determined. Cells treated with SFRP5 exhibited a significant reduction in the expression of catabolic factors with improved expression of anabolic factors, after stimulation with IL-1β (Fig. 4A & Supplementary Fig. S4A, B). Similarly, this treatment suppressed the catabolic process induced by IL-1β in femoral head cartilage (Fig. 4B, C). To obtain additional evidence on the chondroprotective effects of SFRP5, primary murine chondrocytes were stimulated with IL-1β in the presence or absence of SFRP5 and then subjected to bulk RNA-seq analysis. Stimulation of chondrocytes with IL-1β resulted in significant upregulation (FDR > 0.05, FC > 1) of 1736 genes and 1535 genes in the presence of SFRP5 (Fig. 4D). KEGG pathway enrichment analysis revealed that differentially upregulated genes in IL-1β-stimulated chondrocytes were most significantly enriched in the TNF signaling, IL-17 signaling and cytokine‒cytokine receptor interaction pathways (Fig. 4E). GO enrichment for biological processes demonstrated that the upregulated genes in IL-1β-stimulated chondrocytes were most significantly enriched in leukocyte migration and cytokine production (Supplementary Fig. S5). In a manner analogous to that observed in chondrocytes treated with N-β EVs, the expression of genes enriched in the IL-17 signaling, TNF signaling and NF-kappa B signaling pathways was dramatically reduced in IL-1β-stimulated chondrocytes treated with SFRP5 (Fig. 4F, G). Importantly, IL-1β-stimulated chondrocytes treated with SFRP5 exhibited increased expression of genes involved in the TGF-β signaling pathway, such as Smad5 gene (Fig. 4H). Consistent with these results, Western blot analysis demonstrated that treatment with recombinant SFRP5 not only reduced the expression of MMP3 and MMP13 in chondrocytes stimulated with IL-1β but also increased the expression of phospho-SMAD1-5 in these cells (Fig. 4I & Supplementary Fig. S6). These results indicate that SFRP5 exerts chondroprotective effects by decreasing the expression of inflammatory/catabolic factors and transcription factors that mediate catabolic processes in cartilage. Fig. 4Chondroprotective functions of SFRP5 in vitro and ex vivo. A) Effect of SFRP5 treatment on the expression of catabolic factors induced by IL-1β stimulation in primary chondrocytes. B, C) Ex vivo stimulation of mouse cartilage by SFRP5. B) Representative images of Safranin O staining of sectioned femoral head cartilage after stimulation. Scale bars = 50 μm. C) Quantification of Safranin O staining in the superficial zone of sectioned cartilage. D-H) Gene profile of primary chondrocytes stimulated with IL-1β and SFRP5. D) Venn diagram analysis of the genes significantly upregulated in cells stimulated with IL-1β (blue) or IL-1β + SFRP5 (yellow) compared with mock-treated cells and in cells stimulated with IL-1β + SFRP5 (green) compared with those stimulated with IL-1β (n = 3 for each condition). E) Gene enrichment analysis for pathways of differentially upregulated genes in chondrocytes stimulated with IL-1β. F, G) Heatmap showing the expression of genes involved in TNF signaling, inflammatory signaling and catabolic processes in stimulated chondrocytes. H) Heatmap of the expression of genes involved in TGF-β signaling in cartilage. I) Expression of catabolic factors and phosphorylated SMAD1-5 in stimulated chondrocytes. The left panel shows the results of Western blot analysis. The right panel shows the quantification of the relative densities of the detected bands. In the bar charts, the symbols represent individual samples. Significance was determined using one-way analysis of variance. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. ns = not significant Chondroprotective functions of SFRP5 in vitro and ex vivo. A) Effect of SFRP5 treatment on the expression of catabolic factors induced by IL-1β stimulation in primary chondrocytes. B, C) Ex vivo stimulation of mouse cartilage by SFRP5. B) Representative images of Safranin O staining of sectioned femoral head cartilage after stimulation. Scale bars = 50 μm. C) Quantification of Safranin O staining in the superficial zone of sectioned cartilage. D-H) Gene profile of primary chondrocytes stimulated with IL-1β and SFRP5. D) Venn diagram analysis of the genes significantly upregulated in cells stimulated with IL-1β (blue) or IL-1β + SFRP5 (yellow) compared with mock-treated cells and in cells stimulated with IL-1β + SFRP5 (green) compared with those stimulated with IL-1β (n = 3 for each condition). E) Gene enrichment analysis for pathways of differentially upregulated genes in chondrocytes stimulated with IL-1β. F, G) Heatmap showing the expression of genes involved in TNF signaling, inflammatory signaling and catabolic processes in stimulated chondrocytes. H) Heatmap of the expression of genes involved in TGF-β signaling in cartilage. I) Expression of catabolic factors and phosphorylated SMAD1-5 in stimulated chondrocytes. The left panel shows the results of Western blot analysis. The right panel shows the quantification of the relative densities of the detected bands. In the bar charts, the symbols represent individual samples. Significance was determined using one-way analysis of variance. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. ns = not significant Therapeutic effects of SFRP5 on cartilage catabolism in OA models To further verify our findings underlying the chondroprotective effects of SFRP5, ACLT- and collagenase-induced OA mouse models were used. Recombinant SFRP5 was intraarticularly injected 2 times a week, and pathological changes were evaluated after 6 weeks (Fig. 5A). OARSI cartilage scores indicating cartilage degeneration were significantly reduced in mice treated with SFRP5 in both models (Fig. 5A-C). Likewise, SFRP5 treatment reduced the number of MMP13-positive cells and increased number of COL2-positive cells as compared to these received PBS (Supplementary Fig. S7). In contrast, this treatment was not effective to substantially reduce synovitis and osteophytes scores in the knee joints of mice in both models (Supplementary Fig. S8). Our collective data demonstrate that the protective effects of SFRP5 on cartilage degeneration make it a potential therapeutic agent for treating OA. Fig. 5Therapeutic effects of intraarticular injection of SFRP5 on cartilage degeneration and OA progression in 2 experimental OA models. A) Illustration of the experimental procedure showing the schedule of collagenase and SFRP treatment. B-C) Effects of treatment on cartilage degradation as determined by OARS cartilage scores. B) Representative images of Safranin O staining of sectioned distal femoral cartilage and proximal tibial cartilage in mouse knee joints from the ACLT model. The right panel shows the OARS cartilage scores. C) Representative images of Safranin O staining of sectioned distal femoral cartilage and proximal tibial cartilage in mouse knee joints from a collagenase model. The right panel shows the OARS cartilage scores. Scale bars = 200 μm. In the bar charts, the symbols represent individual samples. Significance was determined using one-way analysis of variance. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. ns = not significant Therapeutic effects of intraarticular injection of SFRP5 on cartilage degeneration and OA progression in 2 experimental OA models. A) Illustration of the experimental procedure showing the schedule of collagenase and SFRP treatment. B-C) Effects of treatment on cartilage degradation as determined by OARS cartilage scores. B) Representative images of Safranin O staining of sectioned distal femoral cartilage and proximal tibial cartilage in mouse knee joints from the ACLT model. The right panel shows the OARS cartilage scores. C) Representative images of Safranin O staining of sectioned distal femoral cartilage and proximal tibial cartilage in mouse knee joints from a collagenase model. The right panel shows the OARS cartilage scores. Scale bars = 200 μm. In the bar charts, the symbols represent individual samples. Significance was determined using one-way analysis of variance. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. ns = not significant Discussion The development of more specific and effective treatments for OA requires advancing our understanding of the fundamental cellular processes involved in restoring the homeostatic state of the joint. The intercellular communication among cells within the joint via EVs represents an attractive research area for understanding the pathogenesis of OA and developing new therapeutic strategies. An emerging evidence highlights that neutrophils contribute to the resolution of inflammation in synovial joints and cartilage repair via EVs that enter cartilage to promote TGF-β1 production, ECM deposition and chondrocyte homeostasis [10, 22]. Given the chondroprotective effects of neutrophil-derived EVs in arthritis, we investigated the functional characteristics of EVs derived from stimulated neutrophils and their protective effects on cartilage degeneration in vitro and in vivo OA models. Our results revealed that EVs from TGF-β-stimulated neutrophils exert anti-catabolic and chondroprotective effects with potential therapeutic applications. N-β EV treatment reduced the expression of catabolic factors in IL-1β-stimulated chondrocytes by promoting the expression of SFRP5, which mediates the induction of TGF-β signaling. Exosomes (part of EVs) from different types of stem cells have been implicated in cartilage regulation and regeneration and exhibited protective effects on cartilage in in vitro and in vivo OA models [10, 23]. These findings seem to be consistent with findings underlining the link between EVs, including exosomes and microvesicles of neutrophils, and the induction of TGF-β signaling, which plays a key role in chondrocyte homeostasis and cartilage maintenance. In fact, TGF-β signaling has been shown to promote the biosynthesis of type II collagen and sGAG in chondrocytes, inhibit chondrocyte hypertrophic differentiation, and protect chondrocytes from catabolism induced by proinflammatory cytokines [24–26]. It is expected that the large amount of AnxA1 in neutrophil-derived EVs mediates the induction of TGF-β via the AnxA1-FPR2/ALX axis [27]. However, our results demonstrated that the chondroprotective effects of EVs were not dependent on AnxA1, as neutrophil-derived EVs from AnxA1-deficient mice suppressed the expression of catabolic factors induced by IL-1β stimulation in chondrocytes. In contrast, stimulation with N-β EVs exhibited chondroprotective effects, and this treatment was associated with an increase in SFRP5 in chondrocytes, which exhibited chondroprotective effects and protected cartilage from catabolism in OA model mice. Consistent with these findings, the overexpression of SFRP5 in ATDC5 chondrocytes alleviated LPS-induced inflammation and apoptosis by repressing Wnt5a/JNK activation [28]. Generally, members of the SFRP family have antiangiogenic, anti-inflammatory and antifibrogenic activities via their ability to block the Wnt signaling pathway by interacting with Wnt proteins and preventing them from binding to their frizzled target proteins, which are the upstream components of the Wnt signaling pathway [29]. Similarly, SFRP5 treatment suppresses the production of IL-6 and monocyte chemoattractant protein-1 by repressing NFκB phosphorylation in stimulated adipocytes [30]. Other regulatory effects of SFRP5 in tissues, including adipocyte growth, hepatic steatosis, hepatic lipid metabolism and insulin sensitivity, underline its protective effects against metabolic disorders such as obesity and insulin resistance [31, 32]. Similarly, SFRP5 reduced the expression of catabolic factors and genes involved in the TNF and NFκB signaling pathways in IL-1β-stimulated chondrocytes. The TNF signaling pathway has been implicated in OA progression by inducing chondrocyte apoptosis and downregulating SOX9 expression, which is needed for chondrogenesis [33, 34]. In support of these findings, targeting TNF-α has been shown to be beneficial for improving osteochondral viability, chondrogenesis and the repair of osteochondral lesions in OA [34]. On the other hand, the NF-κB signaling pathway orchestrates the production of matrix-degrading enzymes and proinflammatory mediators in chondrocytes and other cells in the joint [35, 36]. Therefore, upstream regulators of the NF-κB signaling pathway represent potential targets for therapeutic intervention in OA. For instance, targeting IkappaB kinases (IKKs), which are upstream regulators of the NF-κB pathway, suppresses chondrocyte catabolism and cartilage degeneration [37]. Likewise, intra-articular injection of BMS-345,541, a selective inhibitor of IKKα/β, alleviated catabolism and cartilage lesions in an experimental OA model [38]. Another important finding in our study is that the reduction in the expression of genes involved in the TNF and NFκB signaling pathways due to SFRP5 treatment was associated with an increase in the expression of genes involved in TGF-β signaling. Generally, TGF-β has a strong anti-inflammatory effect by repressing the NF-κB signaling pathway, as TGF-β1-deficient mice develop massive inflammation resembling autoimmune disorders [39, 40]. In line with its anti-inflammatory effects, TGF-β1 can stimulate proteoglycan synthesis and protect against proteoglycan loss in cartilage in an arthritis mouse model [41]. Based on these findings, the beneficial effects of SFRP5 observed in vitro and in vivo might be related to its ability to suppress the activation of the TNF and NFκB signaling pathways and induce TGF-β1 signaling in chondrocytes during OA progression. Another possibility for the chondroprotective effects of SFRP5 is that this molecule can neutralize noncanonical c-Jun N-terminal kinase activation resulting in suppression of inflammation and production of metalloproteinases in the tissues [42–44]. Conclusion In conclusion, our study sheds additional light on the beneficial effects of EVs derived from neutrophils in the treatment of OA. SFRP5 is a chondroprotective factor induced by neutrophil-derived EVs in cartilage and can be a promising therapeutic agent for OA. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1